<unk>  is a<unk>  regimen consisting of several (2 to 4)<unk>  monochemotherapies with only one<unk> utic agent per course. The idea behind this approach is that when using single-agent<unk> , the doctor can easily escalate the dose of the drug to the maximum tolerable dose by the patient, avoiding additive hematological toxicity from<unk> utic combinations, and thus improving efficacy. It is mostly used as consolidation therapy for relapsed or refractory lymphomas and relapsed or refractory Hodgkin disease, after DHAP induction. There is also an ongoing trial of this approach in multiple myeloma. __TOC__
Sequential high-dose chemotherapy
Dose-dense chemotherapy
Induction chemotherapy
Multisystemic therapy
Combination therapy
Neoadjuvant therapy
External beam radiotherapy
Chemoimmunotherapy